TY - JOUR
T1 - Modified release of beclometasone dipropionate from chitosan-basedd spray-dried respirable powders
AU - Learoyd, Tristan P.
AU - Burrows, Jane L.
AU - French, Eddie
AU - Seville, Peter C.
PY - 2008/11/20
Y1 - 2008/11/20
N2 - Dry powders for inhalation were prepared by spray drying a 30% v/v aqueous ethanol formulation containing beclometasone dipropionate (BDP), lactose, leucine and chitosan (low, medium or high molecular weight (MW), or combinations thereof). Following physical characterisation of the powders, the aerosolisation and dissolution properties of the powders were investigated using Multi-Stage Liquid Impinger and USP II dissolution apparatus, respectively. The powders were highly dispersible, with emitted doses in excess of 90% of loaded powder aerosolised from a Spinhaler dry powder inhaler. The fine particle fraction (FPF) was observed to decrease, whereas the time for 100% drug release increased, with increasing chitosan MW. For example, the low MW formulation exhibited an FPF of 64% and a 100% dissolution time of 2 h, whereas the high MW formulation demonstrated an FPF of 54% and a dissolution time of 12 h. These powders would be anticipated to deposit predominately in the lower regions of the lung following inhalation, and then undergo delayed rather than instantaneous drug release, offering the potential to reduce dosing frequency and improve patient compliance. (c) 2008 Elsevier B.V. All rights reserved.
AB - Dry powders for inhalation were prepared by spray drying a 30% v/v aqueous ethanol formulation containing beclometasone dipropionate (BDP), lactose, leucine and chitosan (low, medium or high molecular weight (MW), or combinations thereof). Following physical characterisation of the powders, the aerosolisation and dissolution properties of the powders were investigated using Multi-Stage Liquid Impinger and USP II dissolution apparatus, respectively. The powders were highly dispersible, with emitted doses in excess of 90% of loaded powder aerosolised from a Spinhaler dry powder inhaler. The fine particle fraction (FPF) was observed to decrease, whereas the time for 100% drug release increased, with increasing chitosan MW. For example, the low MW formulation exhibited an FPF of 64% and a 100% dissolution time of 2 h, whereas the high MW formulation demonstrated an FPF of 54% and a dissolution time of 12 h. These powders would be anticipated to deposit predominately in the lower regions of the lung following inhalation, and then undergo delayed rather than instantaneous drug release, offering the potential to reduce dosing frequency and improve patient compliance. (c) 2008 Elsevier B.V. All rights reserved.
KW - Spray-drying
KW - Leucine
KW - Modified release
KW - Inhalation
KW - Aerosolisation
KW - Chitosan
UR - http://www.scopus.com/inward/record.url?scp=54549092578&partnerID=8YFLogxK
UR - https://www.sciencedirect.com/science/article/pii/S0032591008001198?via%3Dihub
U2 - 10.1016/j.powtec.2008.02.015
DO - 10.1016/j.powtec.2008.02.015
M3 - Article
SN - 0032-5910
VL - 187
SP - 231
EP - 238
JO - Powder Technology
JF - Powder Technology
IS - 3
ER -